37 results about "Hepatitis B virus surface" patented technology

Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.

The invention relates to application of B-ring ethyoxyl flavanonol in preparing medicaments for treating hepatitis B viruses, in particular to application of a compound as shown in a formula (1) or a medicinal salt thereof in preparing medicaments for clearing away hepatitis B virus surface antigens (HBsAg) and hepatitis B e-antigen (HBeAg) and medicaments for inhibiting the duplication of hepatitis B virus desoxyribonucleic acid (HBV DNA). The compound or the medicinal salt thereof has extremely obvious activity on inhibiting the HBsAg and the HBeAg, and in the presence of a concentration of20 microgram / milliliter, the intensities for clearing away the HBsAg and the HBeAg of the compound or the medicinal salt thereof are respectively 99.8 percent and 48.5 percent and are 6.2 times and 2.7 times of that of alpha-interferon which is a positive control medicament. More importantly, in the presence of the concentration, the inhibition ratio of the compound or the medicinal salt thereof to the HBV DNA is 64.7 percent, and the activity is 1.7 times of that of the alpha-interferon. Accordingly, the flavone lignan or the medicinal salt thereof can be expected to be used for preparing non-nucleoside medicaments for treating infectious diseases of the hepatitis B viruses.

The invention relates to application of a B / E ring substituted silybin for preparing a medicament for treating virus hepatitis B, in particular to the application of a B ring ethoxy and E ring methoxy substituted silybin ester or medicinal salts thereof for preparing the medicament for eliminating hepatitis B virus surface antigens and hepatitis B e antigen and inhibiting HBV and DNA replication. The medicament has accurate activity of inhibiting HBsAg and HbeAg, and respective intensity of 18.5% and 23.0% in eliminating HBsAg and HbeAg at the concentration of 100 microgram / ml, which exceeds the positive control medicament of an alpha-interferon; and meanwhile, 23.3% inhibition ratio on HBV and DNA is displayed at the concentration of 100 microgram / ml; and therefore, flavonoid lignans or a medicinal salt thereof are proved to have the efficacy of inhibiting HbsAg, HbeAg, HBV and DNA. The application is predictably used for preparing the non-nucleoside medicament for eliminating HBsAg and HbeAg, inhibiting HBV and DNA replication and treating hepatitis B virus infectious diseases.

The invention relates to hepatitis B virus (HBV) surface L protein derived peptide which is used for preventing and curing HBV infection, a screening method which is used for removing polypeptide antigenicity and antigenicity-removing derived peptide which is screened and obtained through the screening method. An HBV surface L protein pre-S1 area has a key amino acid sequence of virus adherent cell surface receptors and an antigenicity amino acid sequence which is combined with antibody against L protein. Polypeptide in the HBV surface L protein pre-S1 area can inhibit the infection of the HBV on cells. The invention also provides the screening method which is used for removing polypeptide antigenicity. The antigenicity-removing derived peptide is screened, can inhibit HBV infection and does not combine with the antibody.; Therefore, the mutual interference between natural L protein derived peptide and the antibody against the L protein during HBV infection inhibition is avoided, and both the antigenicity-removing derived peptide and the antibody against the HBV surface L protein can inhibit the HBV infection.

The invention relates to a culture medium supplement, a cell culture medium containing the supplement and applications thereof, the culture medium supplement comprising proline, asparagine and histidine, and / or, transferrin and insulin . The above-mentioned medium supplements can be used for culturing CHO cells specifically expressing hepatitis B virus surface antigen by adding 20-30 mL / L newborn bovine serum to glutamine-free DMEM. The concentration of newborn calf serum used in the cell culture medium provided by the invention is as low as 2%, and it can be directly used for culturing CHO cells by adding specific components, without domesticating the CHO cells, and at the same time, the HBV surface antigen can be expressed in the CHO cells Levels rose, rising 16% to 40% in 13 days.

The invention relates to application of ring A substituted silybin ester in preparing medicaments for treating viral hepatitis B, in particular to application of silybin ester flavonolignan substituted by ethoxycarbonyl methyl on the ring A or a pharmaceutically acceptable salt thereof for preparing medicaments for reducing the hepatitis B virus surface antigen (HBsAg), suppressing the HBV (Hepatitis B Virus) DNA replication and treating HBV infection diseases. The flavonolignan has quite obvious activity on suppressing the HBsAg, and in the presence of a concentration of 100 micrograms / milliliter, the intensity of the flavonolignan for clearing away the HBsAG exceeds that of alpha-interferon which is a positive control medicament by 3.3 times. Meanwhile, in the presence of a concentration of 20 micrograms / milliliter, suppression ratio of the compound to the HBV DNA is close to 60 percent. The pharmacodynamical results indicate that the flavonolignan or the pharmaceutically acceptable salt thereof can be expected to be used for preparing the medicaments for treating the HBV infection diseases.

The invention relates to peptides derived from HBV L protein for the prevention and treatment of Hepatitis B virus (HBV) infection, screening method for removing antigenicity of these peptides and the deantigenic derivative peptide screened through the method, wherein the HBV surface L protein pre-S1 region contains key amino acid sequence of the virus adhesion cell surface acceptor and antigenicamino acid sequence bonding with the anti-L protein antibody. The polypeptides at the HBV surface L protein pre-S1 region can suppress HBV infection to cells. The invention also provides the screening method for removing the antigenicity of these polypeptides.

The invention relates to application of flavone lignan to preparing medicaments for treating virus B hepatitis, in particular to (+ / -)-2-[2,3-dihydro-3-(3,5-dimethoxy-4-hydroxyphenyl)-2-methylol-1,4-benzodioxane-6]-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-ketone or application of medicinal salts thereof to preparing medicaments for treating the virus B hepatitis or preparing medicaments forreducing virus B hepatitis surface antigens (HBsAg). Because the flavone lignan has high-efficiency activity for suppressing the HBsAg, the flavone lignan can be expected to be applied to preparing medicaments for treating the virus B hepatitis.

The present invention provides a method for detecting hepatitis B surface antigen (HBsAg) by inductively coupled plasma mass spectrometry (ICP-MS), which involves covalently linking hepatitis B virus surface antibody (HBsAb) to metal colloid particles with activated carboxyl groups , the HBsAg in the serum and the colloidal particle-labeled HBsAb combine to form an immune complex through a specific reaction; the colloidal particles are dissociated from the immune complex under acidic conditions, and then the metal ion signal is detected by ICP-MS, thereby indirectly detecting HBsAg . Since each colloidal particle can be connected with one or more antibody molecules, the sensitivity of the detection is greatly improved; this method overcomes the disadvantages of low accuracy of the traditional colloidal gold immunochromatography and enzyme-linked immunoassay. It has excellent accuracy and high sensitivity, and the immunoassay detection is convenient and rapid, which broadens the application of ICP-MS in immunoassay.